Pfizer Total Current Liabilities decreased by 7.1% to $34.35B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.8%, from $36.45B to $34.35B. Over 5 years (FY 2020 to FY 2025), Total Current Liabilities shows an upward trend with a 7.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A rising trend relative to current assets may signal liquidity pressure, whereas a stable or declining trend suggests effective management of short-term obligations.
This is the aggregate sum of all financial obligations that the company is required to settle within a twelve-month peri...
Standardized across all public companies; essential for calculating the current ratio and assessing short-term solvency compared to industry peers.
total_current_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.66B | $41.80B | $42.67B | $39.27B | $47.41B | $44.31B | $42.14B | $36.56B | $34.65B | $31.14B | $47.79B | $40.50B | $43.82B | $43.21B | $43.00B | $36.45B | $37.73B | $36.60B | $36.98B | $34.35B |
| QoQ Change | — | +17.2% | +2.1% | -8.0% | +20.7% | -6.5% | -4.9% | -13.2% | -5.2% | -10.1% | +53.5% | -15.3% | +8.2% | -1.4% | -0.5% | -15.2% | +3.5% | -3.0% | +1.1% | -7.1% |
| YoY Change | — | — | — | — | +32.9% | +6.0% | -1.2% | -6.9% | -26.9% | -29.7% | +13.4% | +10.8% | +26.5% | +38.8% | -10.0% | -10.0% | -13.9% | -15.3% | -14.0% | -5.8% |